Retaspimycin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Retaspimycin
Accession Number
DB05626
Type
Small Molecule
Groups
Investigational
Description
Not Available
Structure
Thumb
Synonyms
  • Retaspimycin
External IDs
IPI 504 / IPI-504
Product Ingredients
IngredientUNIICASInChI Key
Retaspimycin hydrochloride928Q33Q049857402-63-2OIRUWDYJGMHDHJ-AFXVCOSJSA-N
Categories
UNII
BZF2ZM0I5Z
CAS number
857402-23-4
Weight
Average: 587.714
Monoisotopic: 587.320665421
Chemical Formula
C31H45N3O8
InChI Key
OAKGNIRUXAZDQF-TXHRRWQRSA-N
InChI
InChI=1S/C31H45N3O8/c1-8-12-33-26-21-13-17(2)14-25(41-7)27(36)19(4)15-20(5)29(42-31(32)39)24(40-6)11-9-10-18(3)30(38)34-22(28(21)37)16-23(26)35/h8-11,15-17,19,24-25,27,29,33,35-37H,1,12-14H2,2-7H3,(H2,32,39)(H,34,38)/b11-9-,18-10+,20-15+/t17-,19+,24+,25+,27-,29+/m1/s1
IUPAC Name
(4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13,20,22-trihydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3-oxo-19-[(prop-2-en-1-yl)amino]-2-azabicyclo[16.3.1]docosa-1(22),4,6,10,18,20-hexaen-9-yl carbamate
SMILES
CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(O)=CC(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)=C2O

Pharmacology

Indication

Investigated for use/treatment in gastric cancer, lung cancer, and multiple myeloma.

Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
25038261
ChEBI
71975
ChEMBL
CHEMBL1184904

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentGastrointestinal Stromal Tumors / Soft Tissue Sarcoma (STS)1
1CompletedTreatmentMultiple Myeloma (MM)1
1CompletedTreatmentTumors, Solid1
1, 2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1, 2CompletedTreatmentLung Cancers1
1, 2WithdrawnTreatmentCancer, Breast1
2CompletedTreatmentCancer of the Prostate / Prostate Cancer / Prostatic Neoplasms1
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2TerminatedTreatmentCancer of the Breast / Cancer, Breast / HER2 Positive Breast Cancers / Metastatic Breast Cancer (MBC)1
2TerminatedTreatmentLung Cancers / Stage IIIb Lung Cancer / Stage IV Lung Cancer1
2TerminatedTreatmentMetastatic Melanoma1
2WithdrawnTreatmentLiposarcomas, Dedifferentiated1
3TerminatedTreatmentGastrointestinal Stromal Tumors1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0174 mg/mLALOGPS
logP3.96ALOGPS
logP3.8ChemAxon
logS-4.5ALOGPS
pKa (Strongest Acidic)9.62ChemAxon
pKa (Strongest Basic)4.55ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count6ChemAxon
Polar Surface Area172.6 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity166.79 m3·mol-1ChemAxon
Polarizability63.4 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as macrolactams. These are cyclic amides of amino carboxylic acids, having a 1-azacycloalkan-2-one structure, or analogues having unsaturation or heteroatoms replacing one or more carbon atoms of the ring. They are nitrogen analogues (the a nitrogen atom replacing the o atom of the cyclic carboxylic acid group ) of the naturally occurring macrolides.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Macrolactams
Sub Class
Not Available
Direct Parent
Macrolactams
Alternative Parents
Secondary alkylarylamines / 1-hydroxy-2-unsubstituted benzenoids / Carbamate esters / Secondary carboxylic acid amides / Secondary alcohols / Organic carbonic acids and derivatives / Lactams / Polyols / Dialkyl ethers / Azacyclic compounds
show 4 more
Substituents
Macrolactam / 1-hydroxy-2-unsubstituted benzenoid / Secondary aliphatic/aromatic amine / Benzenoid / Carbamic acid ester / Amino acid or derivatives / Carboxamide group / Lactam / Carbonic acid derivative / Secondary alcohol
show 19 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
lactam, macrocycle, hydroquinones (CHEBI:71975)

Drug created on November 18, 2007 11:26 / Updated on September 02, 2019 21:58